Vlado Perkovic's Publications

• Renal trials in diabetes need a platform: time for a global approach?

  Journal articles

  2018

  The Lancet Diabetes and Endocrinology

• CANAGLIFLOZIN AND RENAL OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

  Conference Abstracts

  2018

  AMERICAN JOURNAL OF KIDNEY DISEASES

• Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAsupsup): A randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

  Journal articles

  2018

  Cardiovascular Diabetology

• Are SGLT2 inhibitors ready for prime time for CKD?

  Journal articles

  2018

  Clinical Journal of the American Society of Nephrology

• Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology

  Journal articles

  2018

  Kidney International Supplements

• Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

  Journal articles

  2018

  Circulation

• Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS program

  Journal articles

  2018

  Circulation

• New hypoglycemic agents and the kidney: What do the major trials tell us?.

  Journal articles

  2018

  F1000Research

• ACCORDION: Ensuring that we hear the music clearly

  Journal articles

  2018

  Clinical Journal of the American Society of Nephrology

• Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function data from the CANVAS program

  Journal articles

  2018

  Circulation

• Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists Collaboration

  Book Chapters

  2018

  Hypertension: A Companion to Braunwalds Heart Disease

• Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results from ADVANCE-ON

  Journal articles

  2018

  Diabetes Care

• The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics

  Journal articles

  2018

  American Journal of Nephrology

• Abstract 233 Outcomes with Canagliflozin in Patients By Age Subgroups: Results from the Canvas Program

  Journal articles

  2018

  Endocrine Practice

• 47 Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists Collaboration

  Book Chapters

  2018

  Hypertension: A Companion to Braunwalds Heart Disease

• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Reply

  Journal articles

  2017

  NEW ENGLAND JOURNAL OF MEDICINE

• The authors reply

  Journal articles

  2017

  New England Journal of Medicine

• Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

  Conference Papers

  2017

  CIRCULATION

• Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial

  Journal articles

  2017

  Diabetes, Obesity and Metabolism

• Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy

  Journal articles

  2017

  The Lancet

• Action plan for optimizing the design of clinical trials in chronic kidney disease

  Journal articles

  2017

  Kidney International Supplements

• Closing the gap between evidence and practice in chronic kidney disease

  Journal articles

  2017

  Kidney International Supplements

• Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis

  Journal articles

  2017

  PLoS ONE

• Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data

  Journal articles

  2017

  The Lancet Diabetes and Endocrinology

• Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial

  Journal articles

  2017

  Drugs in R and D

• Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: Should unstable angina be included in the primary end point?

  Journal articles

  2017

  Diabetes Care